Overview

A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The aim of BEVAMAINT is to improve benefic effect of maintenance therapy after a first line of induction chemotherapy for patients with colorectal cancer

Phase:

Phase 3

Details

Lead Sponsor:

Centre Hospitalier Universitaire Dijon

Treatments:

Bevacizumab